What is the active molecule in the antidepressant Cipralex?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 8, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cipralex Active Molecule

The active molecule in Cipralex is escitalopram (escitalopram oxalate), which is the therapeutically active S-enantiomer of the racemic compound citalopram 1, 2.

Chemical Identity and Mechanism

Escitalopram is a highly selective serotonin reuptake inhibitor (SSRI) that works by potently inhibiting the serotonin transporter protein in the central nervous system 3, 1. This selective inhibition increases serotonergic activity by preventing serotonin reuptake into presynaptic nerve terminals.

Key Distinguishing Features:

  • Enantiomeric specificity: Escitalopram is the isolated S-enantiomer extracted from racemic citalopram (RS-citalopram), making it approximately 8 times more potent than its metabolites in inhibiting serotonin reuptake 3

  • High selectivity: It demonstrates minimal effects on norepinephrine and dopamine reuptake, with very low affinity for other receptor systems including 5-HT1A, 5-HT2A, dopamine, adrenergic, histamine, GABA, muscarinic cholinergic, and benzodiazepine receptors 3

Clinical Formulation

The drug contains escitalopram hydrobromide as the active pharmaceutical ingredient 3. The inactive ingredients include copovidone, corn starch, croscarmellose sodium, lactose monohydrate, magnesium stearate, hypromellose, microcrystalline cellulose, polyethylene glycol, and titanium dioxide, with iron oxides used as coloring agents in certain tablet strengths 3.

Important Pharmacokinetic Considerations:

The metabolism of escitalopram occurs primarily through CYP3A4 and CYP2C19 enzymes 3. This is clinically relevant because CYP2C19 poor metabolizers show 68% higher peak concentrations and 107% higher drug exposure compared to normal metabolizers, which may necessitate dose adjustments 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.